Based on the Biogen Inc stock forecasts from 19 analysts, the average analyst target price for Biogen Inc is USD 262.33 over the next 12 months. Biogen Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Biogen Inc is Neutral, which is based on 8 positive signals and 7 negative signals. At the last closing, Biogen Inc’s stock price was USD 276.61. Biogen Inc’s stock price has changed by +38.76% over the past week, +39.29% over the past month and -2.85% over the last year.

2. Page 1 of 10 Any information in this report is not , and should not be regarded as investment advice or as a recommendation regarding any particular security or course of
action. We recommend seeking a licensed professional for investment advice.
BIIB:NSD (Biogen Inc)
Drug Manufacturers-General | NSD | Common Stock
Values as of 28th Sep, 2022
Stock Target Advisor
Detailed Stock Report
Report Date: 29th September, 2022
Last Close
USD 276.61
Change
+78.82(+39.85%)
Market Cap
USD 28.41B
1 Yr Capital Gain
-3.13%
1 Yr Dividend Return
N/A
1 Yr Total
Return
-3.13%
Earning Growth (5 yr)
-57.98%
Average Target Price
262.33(-5.16% )
Average Analyst
Rating
Strong Buy
Fundamental
Analysis
Neutral
Our view of the stock is Neutral with a score of 5.3 out of 10, where 0 is very bearish and 10 very bullish
What to like
Underpriced compared to earnings
The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to
make sure there is no specific reason.
Underpriced on cashflow basis
The stock is trading low compared to its peers on a price to cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to
make sure there is no specific reason.
Superior capital utilization
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Underpriced on free cash flow basis
The stock is trading low compared to its peers on a price to free cash flow basis and is in the top quartile. It may be underpriced but do check its financial
performance to make sure there is no specific reason.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in
the long run.
What to not like
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique
technology or market which can help it grow or get acquired in future.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are
considering to buy.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector

3. Page 3 of 10 Any information in this report is not , and should not be regarded as investment advice or as a recommendation regarding any particular security or course of
action. We recommend seeking a licensed professional for investment advice.
BIIB:NSD (Biogen Inc)
Drug Manufacturers-General | | Common Stock
Stock Target Advisor
Detailed Stock Report
Report Date: 29th September, 2022
Adjusted Closing Share Volume
Relative Returns Relative Performance (Total Returns)
Security Capital Gain Dividend Return Total Return
BIIB
Biogen Inc
-2.8% 0 -2.8%
QQQ
Invesco QQQ Trust
-22.2% +0.4% -21.8%
Company Overview
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The
company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal
muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL;
ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab
biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic
leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's
lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and
other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab,
Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat
neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125
and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to
treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of
development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited;
Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.;
Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge,
Massachusetts.

4. Page 4 of 10 Any information in this report is not , and should not be regarded as investment advice or as a recommendation regarding any particular security or course of
action. We recommend seeking a licensed professional for investment advice.
Company Website
https://www.biogen.com
Address
225 Binney Street, Cambridge, MA, United States, 02142
Fiscal Year End
December
Employees
9610
Technical Indicators
Value Value
Beta 0.42 52 Week High 290.76
Short Ratio 2.53 52 Week Low 187.16
Shorted Shares 2,074,132 200 Day Moving Average 212.71
Shorted Shares Previous Month 1,888,020 50 Day Moving Average 209.48
Shares Held By Insiders 68.60% Short Percentage 2.00%
Shares Held by Institutions 86.46 Dividend Yield N/A

5. Page 5 of 10 Any information in this report is not , and should not be regarded as investment advice or as a recommendation regarding any particular security or course of
action. We recommend seeking a licensed professional for investment advice.
BIIB:NSD (Biogen Inc)
Drug Manufacturers-General | | Common Stock
Stock Target Advisor
Detailed Stock Report
Report Date: 29th September, 2022
Market Performance
Market Performance vs. Industry / Classification (Drug Manufacturers-General) Market Performance vs. Exchange (Nasdaq Global Select)
Value Sector Median
Percentile
Rank
Grade Market Median Percentile Rank Grade
YTD
Capital Gain 15.29% -40.8% 100% -27.0% 95%
Dividend Return N/A 2.6% N/A 1.7% N/A
Total Return 15.29% -40.8% 100% -25.9% 95%
Trailing 12 Months
Capital Gain -3.13% -41.9% 89% -29.0% 76%
Dividend Return N/A 3.5% N/A 2.4% N/A
Total Return -3.13% -41.9% 89% -27.2% 74%
Trailing 5 Years
Capital Gain -11.66% -11.7% 57% -8.2% 47%
Dividend Return N/A 16.1% N/A 10.5% N/A
Total Return -11.66% -5.0% 29% 2.3% 39%
Average Annual (5 Year Horizon)
Capital Gain -5.73% -3.2% 25% 0.2% 30%
Dividend Return N/A 3.0% N/A 1.8% N/A
Total Return -5.73% 0.6% 25% 0.7% 29%
Risk Return Profile
Volatility (Standard
Deviation)
21.14% 17.4% 25% 33.4% 70%
Risk Adjusted Return -27.10% N/A 25% 10.9% 33%
Market Capitalization 28.41B 28.41B 50% 5.68B 98%

6. Page 6 of 10 Any information in this report is not , and should not be regarded as investment advice or as a recommendation regarding any particular security or course of
action. We recommend seeking a licensed professional for investment advice.
Key Financial Ratios
Ratios vs. Industry / Classification (Computer Hardware) Ratios vs. Exchange (Nasdaq Global Select)
Value Sector Median
Percentile
Rank
Grade Market Median Percentile Rank Grade
Market Value
peratio 14.2 19.3 100% 16.8 57%
pbratio 2.4 2.9 71% 1.4 32%
pcfratio 7.8 9.5 75% -1.2 26%
pfcfratio 10.1 12.4 88% 0.0 22%
Management Effectiveness
retequity 13.65% 13.7% 57% -7.0% 80%
retinvcap 15.36% 3.9% 78% -1.5% 83%
retass 7.45% 5.5% 75% -0.9% 90%
debtequityratio 57.58% 71.6% 71% 30.2% 34%
Technical Ratios
yield N/A 3.4% N/A 3.0% N/A
sratio 2.53 2.53 50% 2.67 51%
spercent 1.47% 1.5% 50% 2.3% 60%
beta 0.42 0.42 43% 1.06 86%

7. Page 7 of 10 Any information in this report is not , and should not be regarded as investment advice or as a recommendation regarding any particular security or course of
action. We recommend seeking a licensed professional for investment advice.
BIIB:NSD (Biogen Inc)
Drug Manufacturers-General | | Common Stock
Stock Target Advisor
Detailed Stock Report
Report Date: 29th September, 2022
Recent Analyst Ratings
Price Action Rating Action Analyst Rating Price date
Upgraded by Robert W Baird Neutral » Outperform USD 224 » USD 340 2022-09-28
Maintains Wells Fargo Overweight USD 265 » USD 350 2022-09-28
Upgraded by BMO Financial
Market Perform »
Outperform
USD 217 » USD 360 2022-09-28
Upgrades Mizuho Securities Buy USD 207 » USD 270 2022-09-28
Maintains RBC Royalbank Outperform USD 251 » USD 321 2022-09-28
Maintains Piper Sandler Neutral USD 200 » USD 280 2022-09-28
Maintains Wedbush Neutral USD 183 » USD 217 2022-09-28
Maintains Truist Securities Buy USD 270 » USD 265 2022-09-22
Reiterated by Jefferies Financial LLC Buy » Buy USD 300 2022-09-20
Target Down Stifel Nicolaus Research USD 223 2022-09-13
Target Up JP Morgan & Company USD 221 2022-07-22
Target Down Guggenheim Securities USD 190 2022-07-22
Target Down RBC Royalbank USD 259 2022-07-22
Target Down UBS USD 238 2022-07-22
Maintains Barclays Equal-Weight USD 210 » USD 200 2022-07-21
Maintains Cowen Outperform USD 285 » USD 270 2022-07-21
Maintains Needham & Company LLC Buy USD 262 » USD 250 2022-07-21
Maintains Truist Securities Buy USD 320 » USD 270 2022-07-21
Raised BMO Financial USD 217 2022-07-19
Maintains Oppenheimer Holdings Outperform USD 225 » USD 230 2022-07-18
Raised RBC Royalbank USD 273 2022-06-20
Target Lowered by SVB Leerink Outperform USD 300 » USD 270 2022-04-21
Upgraded by Wells Fargo
Equal Weight »
Overweight
USD 235 » USD 265 2022-04-18
Target Lowered by Morgan Stanley Overweight USD 330 » USD 283 2022-04-12
Target Lowered by Barclays USD 235 » USD 219 2022-04-12

8. Page 8 of 10 Any information in this report is not , and should not be regarded as investment advice or as a recommendation regarding any particular security or course of
action. We recommend seeking a licensed professional for investment advice.
BIIB:NSD (Biogen Inc)
Drug Manufacturers-General | | Common Stock
Stock Target Advisor
Detailed Stock Report
Report Date: 29th September, 2022
Annual Financial (USD)

9. Page 9 of 10 Any information in this report is not , and should not be regarded as investment advice or as a recommendation regarding any particular security or course of
action. We recommend seeking a licensed professional for investment advice.
BIIB:NSD (Biogen Inc)
Drug Manufacturers-General | | Common Stock
Stock Target Advisor
Detailed Stock Report
Report Date: 29th September, 2022
Quarterly Financial (USD)

10. Page 10 of 10 Any information in this report is not , and should not be regarded as investment advice or as a recommendation regarding any particular security or course of
action. We recommend seeking a licensed professional for investment advice.
BIIB:NSD (Biogen Inc)
Drug Manufacturers-General | | Common Stock
Stock Target Advisor
Detailed Stock Report
Report Date: 29th September, 2022
Largest Industry Peers for Drug Manufacturers-General
Symbol Company Name Price(Change) Market Cap
AZN AstraZeneca PLC ADR +1.45 (+2.7%) USD 167.72B
AMGN Amgen Inc +4.99 (+2.2%) USD 121.41B
SNY Sanofi ADR +0.95 (+2.6%) USD 93.61B
GILD Gilead Sciences Inc +1.30 (+2.1%) USD 78.79B
CELG Celgene Corporation N/A USD 77.04B
HZNP Horizon Pharma PLC +1.67 (+2.7%) USD 14.51B
GWPH GW Pharmaceuticals plc N/A USD 6.81B
GRFS Grifols SA ADR -0.11 (-1.7%) USD 5.68B
TSVTV 2seventy bio Inc. Common Stock.. N/A USD 0.62B
CRXT Clarus Therapeutics Holdings I.. +0.01 (+26.2%) USD 2.47M
ETFs Containing BIIB
Symbol Company Name Weight Mer Price(Change) Market Cap
UBIO ProShares UltraPro Nasdaq Biot.. 6.30 % 0.95 % N/A USD 0.02B
BIOT:LSE L&G Pharma Breakthrough UCITS .. 4.43 % 0.00 % N/A USD 8.18M
BTEE:LSE iShares Nasdaq US Biotechnolog.. 0.00 % 0.00 % +0.17 (+4.0%) USD 0.43B
FHH-F:CA First Trust AlphaDEX U.S. Heal.. 0.00 % 0.00 % N/A USD 0.02B
W311:XETRA HAN-GINS Indxx Healthcare Mega.. 0.00 % 0.00 % +0.17 (+4.0%) USD 0.01B
BIOT Biotech Acquisition Co 0.00 % 0.00 % N/A USD 0.29B
OSX2:XETRA Ossiam US Minimum Variance ESG.. 0.00 % 0.00 % +3.50 (+4.0%) USD 0.11B
CEM2:XETRA iShares US Equity Buyback Achi.. 0.00 % 0.00 % N/A USD 4.53M
BBCK:XETRA Invesco Global Buyback Achieve.. 0.00 % 0.00 % +0.33 (+4.0%) USD 0.06B
2B70:XETRA iShares Nasdaq US Biotechnolog.. 0.00 % 0.00 % +0.16 (+4.0%) USD 0.46B
The Stock Target Advisor platform run millions of calculations every day on over 30,000 Canadian and American stocks, comparing and
ranking their financial and market performance against their sectors and exchange.
We represent the percentile ranking using the following grading system.
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%